Search

Your search keyword '"CIGOLARI S"' showing total 16 results
Start Over Author "CIGOLARI S" Publisher elsevier bv
16 results on '"CIGOLARI S"'

1. Cisplatin, fotemustine and whole-brain radiotherapy in non-small cell lung cancer patients with asymptomatic brain metastases: A multicenter phase II study of the Gruppo Oncologico Italia Meridionale (GOIM 2603)

Author

Galetta, D., primary, Gebbia, V., additional, Silvestris, N., additional, Ferraù, F., additional, Carrozza, F., additional, Cigolari, S., additional, Russo, P., additional, Calista, F., additional, Adamo, V., additional, and Colucci, G., additional

Published
2011
Full Text
View/download PDF

3. Activity and tolerability of Cisplatin (CDDP) and Fotemustine (FTM) combination in the treatment of patients with non-small cell lung cancer (NSCLC) with brain metastases (BM): A multicentric phase II study of the Gruppo Oncologico dell’Italia Meridionale (GOIM)

Author

Galetta, D., primary, Gebbia, V., additional, Romito, S., additional, Ferraù, F., additional, De Marinis, F., additional, Cigolari, S., additional, Adamo, S., additional, and Colucci, G., additional

Published
2008
Full Text
View/download PDF

4. 5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: A multicenter randomised phase II study of the Southern Italy Oncology Group

Author

Maiello, E., primary, Gebbia, V., additional, Giuliani, F., additional, Paoletti, G., additional, Gebbia, N., additional, Cigolari, S., additional, Fortunato, S., additional, Pedicini, T., additional, Borsellino, N., additional, Lopez, M., additional, and Colucci, G., additional

Published
2000
Full Text
View/download PDF

5. Amifostine plus cisplatin plus vinorelbine in the treatment of advanced non small cell lung cancer: a multicenter phase II study

Author

Gridelli, C, primary, Cigolari, S, additional, Maiorino, A, additional, Ianniello, G.P, additional, Brancaccio, L, additional, Rossi, A, additional, De Cataldis, G, additional, Pedicini, T, additional, Maiorino, L, additional, Barletta, E, additional, Di Lanno, M, additional, Bilancia, D, additional, Crispino, C, additional, Barzelloni, M.L, additional, Masullo, P, additional, D’Aniello, R, additional, and Manzione, L, additional

Published
2000
Full Text
View/download PDF

7. Carboplatin plus vinorelbine: A new active regimen in extensive small cell lung cancer. Results of a multicenter phase II study

Author

Gridelli, C., primary, lanniello, G., additional, Brancaccio, L., additional, Perrone, F., additional, laffaioli, R.V., additional, Curcio, C., additional, D’Aprile, M., additional, Cioffi, R., additional, Cigolari, S., additional, Rossi, A., additional, Rinaldi, L., additional, Palazzolo, G., additional, Garcia, M., additional, Guida, C., additional, Bianco, A.R., additional, Pergola, M., additional, and Monfardini, S., additional

Published
1997
Full Text
View/download PDF

10. 212 Carboplatin plus vinorelbine: A new active regimen in extensive small cell lung cancer. Results of a multicenter phase II study

Author

Gridelli, C., primary, Ianniello, G., additional, Brancaccio, L., additional, Perrone, F., additional, Iaffaioli, R.V., additional, Curcio, C., additional, D'Aprile, M., additional, Cioffi, R., additional, Cigolari, S., additional, Rossi, A., additional, Rinaldi, L., additional, Veltri, E., additional, Palazzolo, G., additional, Leo, L., additional, Bianco, A.R., additional, Pergola, M., additional, and Monfardini, S., additional

Published
1997
Full Text
View/download PDF

11. 39 Six year follow up of the European Multicentre Randomised Study comparing Navelbine (NVB) alone vs NVB + Cisplatin (CDDP) vs Vindesine (VDS) + CDDP in 612 patients (pts) with advanced non-small cell lung cancer (NSCLC)

Author

Le Chevalier, T., primary, Pujol, J.L., additional, Douilard, J.Y., additional, Alberola, V., additional, Monnier, A., additional, Rivière, A., additional, Cigolari, S., additional, Ruffié, P., additional, Panizo, A., additional, Guillem, V., additional, Besson, P.F., additional, Danel, P., additional, Brisgand, D., additional, Berthaud, P., additional, Larriba, J.L.G., additional, and Martinez, A., additional

Published
1997
Full Text
View/download PDF

12. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study

Author

Gridelli, C., primary, Perrone, F., additional, Gallo, C., additional, De Marinis, F., additional, Ianniello, G., additional, Cigolari, S., additional, Cariello, S., additional, Di Costanzo, F., additional, D'Aprile, M., additional, Rossi, A., additional, Migliorino, R., additional, Bartolucci, R., additional, Bianco, A.R., additional, Pergola, M., additional, and Monfardini, S., additional

Published
1997
Full Text
View/download PDF

16. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study

Author

Alessandra Rossi, C. Gridelli, M. D'Aprile, R. Migliorino, S. Cigolari, Ciro Gallo, S. Cariello, Ar Bianco, F. De Marinis, F. Di Costanzo, R. Bartolucci, Silvio Monfardini, M. Pergola, F. Perrone, G P Ianniello, Gridelli, C, Perrone, F, Gallo, Ciro, DE MARINIS, F, Ianniello, G, Cigolari, S, Cariello, S, DI COSTANZO, F, D'Aprile, M, Rossi, A, Migliorino, R, Bartolucci, R, Bianco, Ar, Pergola, M, and Monfardini, S.

Subjects
Male, Cancer Research, medicine.medical_specialty, Lung Neoplasms, medicine.medical_treatment, Phases of clinical research, ECOG Performance Status, Vinblastine, Vinorelbine, Drug Administration Schedule, Carcinoma, Non-Small-Cell Lung, Internal medicine, medicine, Humans, Lung cancer, Aged, Aged, 80 and over, Chemotherapy, Performance status, business.industry, Age Factors, medicine.disease, Antineoplastic Agents, Phytogenic, Surgery, Survival Rate, Clinical trial, Oncology, Tolerability, Female, business, medicine.drug
Abstract

More than 30% of lung cancers arise in patients aged 70 years or more; however, because elderly patients are not considered to tolerate chemotherapy, they are generally excluded from clinical trials and are not considered eligible for aggressive cisplatin-based chemotherapy in clinical practice. The aims of the present study were to test tolerability and activity of weekly vinorelbine in advanced non-small cell lung cancer (NSCLC) patients aged 70 years or more, and to define whether minimum conditions existed for a randomised comparison with best supportive care. The study was designed as a multicentre two-stage phase II trial according to Simon's optimal design: 8 or more responses out of 43 treated patients were expected at the end of the trial. Patients aged 70 years or more were eligible if they had a cytological or histological diagnosis of NSCLC at stage IIIb–IV and a performance status less than or equal to two according to the ECOG scale. Vinorelbine was given intravenously (i.v.) at a dose of 30 mg/m 2 every week for 12 doses. As planned, 43 patients entered the study; median age was 73 years (range 70–80); 11 patients were older than 75 years. Median dose-intensity (mg/m 2 /week) of vinorelbine was 21.2 (range 7.5–30) and was not affected by age of patients. Toxicity was generally mild, mainly haematological and never life-threatening. ECOG performance status improved in 26% of patients; cough and pain improved in more than 40% of patients symptomatic at entry, while dyspnoea improved in 28%; approximately half the patients had a stabilisation of their symptoms. 10 patients (23–95% exact confidence interval (CI): 12–39%) obtained a partial response. Median time to progression was 11 weeks (95% CI 8–30) and median survival 36 weeks (95% CI 28–53). One-year estimated progression-free and overall survival rates are 16% and 36%, respectively. In conclusion, vinorelbine was well tolerated and active in the treatment of elderly NSCLC patients. A phase III trial (ELVIS—Elderly Lung Cancer Vinorelbine Italian Study) comparing best supportive care versus best supportive care plus vinorelbine is now ongoing.

Published
1997
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results